PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
The complement system, a central arm of innate immunity, comprises a network of plasma and membrane-bound proteins that detect and eliminate pathogens. In severe COVID-19, SARS-CoV-2 triggers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results